Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Dna X (SONM) EBT (2018 - 2025)

Dna X's EBT history spans 8 years, with the latest figure at $3.5 million for Q4 2025.

  • Quarterly results put EBT at $3.5 million for Q4 2025, down 61.07% from a year ago — trailing twelve months through Dec 2025 was -$8.0 million (down 175.93% YoY), and the annual figure for FY2025 was -$8.0 million, down 175.93%.
  • EBT for Q4 2025 was $3.5 million at Dna X, up from -$4.7 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $8.9 million in Q4 2024 to a low of -$11.8 million in Q4 2021.
  • The 5-year median for EBT is -$2.6 million (2024), against an average of -$3.1 million.
  • Peak annual rise in EBT hit 1162.51% in 2024, while the deepest fall reached 1232.36% in 2024.
  • Year by year, EBT stood at -$11.8 million in 2021, then surged by 91.01% to -$1.1 million in 2022, then grew by 21.15% to -$835000.0 in 2023, then skyrocketed by 1162.51% to $8.9 million in 2024, then tumbled by 61.07% to $3.5 million in 2025.
  • According to Business Quant data, EBT over the past three periods came in at $3.5 million, -$4.7 million, and -$7.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.